Envista Holdings Corporation
Financials
Valuation Metrics
Envista Holdings Corporation's Market Cap is $4.46B. At end of 2025 it was $3.57B. Ranked #1471 of 3,111 in US market (top 47%), #963 of 1,666 on NYSE (top 58%), #85 of 206 in Health Care Equipment & Services (top 41%) by Market Cap.
Investment Metrics(as of 2026-08-03)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | $4.46B | US#1,471/3,111 Sec#85/206 |
| Revenue | $2.81B | US#1,282/3,111 Sec#77/206 |
| Net Income | $68M | US#1,753/3,111 Sec#83/206 |
| Total Assets | $5.58B | US#1,371/3,111 Sec#65/206 |
| Net Assets | $3.08B | US#969/3,111 Sec#50/206 |
| Employees | 12,000 | US#539/3,111 Sec#50/206 |
| Value | ||
| P/E | 65.82x | US#1,976/3,111 Sec#98/206 |
| P/B | 1.45x | US#785/3,111 Sec#46/206 |
| PEG | 0.57x | US#607/3,111 Sec#20/206 |
| P/S | 1.59x | US#1,034/3,111 Sec#74/206 |
| EV/EBITDA | 14.31x | US#1,410/3,111 Sec#55/206 |
| FCF Yield | 4.94% | US#1,299/3,111 Sec#66/206 |
| Profitability | ||
| ROE | 2.20% | US#2,044/3,111 Sec#101/206 |
| ROA | 1.21% | US#1,854/3,111 Sec#106/206 |
| Op. Margin | 9.04% | US#1,708/3,111 Sec#83/206 |
| Revenue Growth | 14.36% | US#1,000/3,111 Sec#67/206 |
| Earnings Growth | 115.00% | US#309/3,111 Sec#12/206 |
| Financial Health | ||
| Debt Ratio | 81.13% | US#892/3,111 Sec#93/206 |
| Total Debt | $1.59B | US#1,279/3,111 Sec#64/206 |
| FCF | $220M | US#1,314/3,111 Sec#77/206 |
| Cash | $1.08B | US#654/3,111 Sec#37/206 |
| Current Ratio | 2.44x | US#1,019/3,111 Sec#102/206 |
| Net Debt/EBITDA | 1.46x | US#1,162/3,111 Sec#65/206 |
| Performance | ||
| 1Y Return | 31.47% | US#811/3,111 Sec#58/206 |
| 1M Return | -0.89% | US#1,461/3,111 Sec#109/206 |
| From 52W High | -9.98% | US#1,006/3,111 Sec#62/206 |
| 1Y MDD | -25.97% | US#1,092/3,111 Sec#31/206 |
| Trading | ||
| Volume | 2,556,772 shares | US#711/3,111 Sec#42/206 |
| Trading Value | $70M | US#1,122/3,111 Sec#74/206 |
| Per Share | ||
| EPS | $0.29 | US#1,945/3,111 Sec#101/206 |
| BPS | $18.89 | US#1,260/3,111 Sec#71/206 |
Company Info
Envista Holdings Corporation, together with its subsidiaries, develops, manufactures, markets, and sells dental products in the United States, China, and internationally. The company operates in two segments, Specialty Products & Technologies, and Equipment & Consumables. The Specialty Products & Technologies segment offers dental implant systems, guided surgery systems, biomaterials, and prefabricated and custom-built prosthetics to oral surgeons, prosthodontists and periodontists, and general dentist; and brackets and wires, tubes and bands, archwires, clear aligners, digital orthodontic treatments, retainers, and other orthodontic laboratory products, as well as provides DTX Studio Clinic, a software package offered with its imaging products. This segment offers its products under the Nobel Biocare, Alpha-Bio Tec, Implant Direct, Nobel Procera, Ormco, Spark, Orascoptic, Damon, Insignia, AOA brands. The Equipment & Consumables segment provides dental equipment and supplies, including digital imaging systems, software, and other visualization/magnification systems; endodontic systems and related products; restorative materials, rotary burs, impression materials, bonding agents, and cements; and infection prevention products. This segment offers its products under the Dexis, DTX Studio, Kerr, Metrex, Total Care, Pentron, Optibond, Harmonize, Sonicfill, Sybron Endo, and CaviWipes to dental offices, clinics, and hospitals. Envista Holdings Corporation was incorporated in 2018 and is headquartered in Brea, California.